Gary Richardson
- Oncology top 1%
- Colorectal Cancer Treatments and Studies 13
- Lung Cancer Research Studies 13
- Cancer Treatment and Pharmacology 12
- HER2/EGFR in Cancer Research 9
- Hepatology top 2%
-
- Lung Cancer Treatments and Mutations 24
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 9
-
- Monoclonal and Polyclonal Antibodies Research 13
-
- Ovarian cancer diagnosis and treatment 12
Gary Richardson
104 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Oncology 2.6k
- Hepatology 319
- Pulmonary and Respiratory Medicine 1.2k
- Cancer Research 429
- Pathology and Forensic Medicine 475
Countries citing papers authored by Gary Richardson
This map shows the geographic impact of Gary Richardson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Richardson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Richardson more than expected).
Fields of papers citing papers by Gary Richardson
This network shows the impact of papers produced by Gary Richardson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Richardson. The network helps show where Gary Richardson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gary Richardson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2024 | 0 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 0 | |
| 8 | 2023 | 2 | |
| 9 | 2017 | 12 | |
| 10 | 2017 | 17 | |
| 11 | 2017 | 2 | |
| 12 | 2015 | 8 | |
| 13 | 2015 | 2 | |
| 14 | Treatment effect of panitumumab in subsets by epidermal growth factor receptor (EGFR) status from a phase 3 randomized controlled trial | 2006 | 2 |
| 15 | 2000 | 13 | |
| 16 | 1999 | 10 | |
| 17 | 1997 | 52 | |
| 18 | 1996 | 2 | |
| 19 | 1995 | 46 | |
| 20 | 1991 | 6 |
About Gary Richardson
Gary Richardson is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine, having authored 110 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), Monoclonal and Polyclonal Antibodies Research (13 papers), Colorectal Cancer Treatments and Studies (13 papers), Lung Cancer Research Studies (13 papers), Cancer Treatment and Pharmacology (12 papers), Ovarian cancer diagnosis and treatment (12 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Genomics and Diagnostics (9 papers). The work is most often cited by research in Oncology (2.6k citations), Hepatology (319 citations) and Pulmonary and Respiratory Medicine (1.2k citations). Gary Richardson has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Salvatore Siena, Bart Neyns, Yves Humblet, Eric Van Cutsem, Marc Peeters, Joan Maurel, Alain Hendlisz, Jean–Luc Van Laethem, Rafael G. Amado and Jean-Luc Canon. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Cancer and Bone Marrow Transplantation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.